The Japanese Pharmaceutical Market Has Become Increasingly Difficult

Research and Markets (http://www.researchandmarkets.com/reportinfo.asp?report_id=43085) has announced the addition of the “Takeda Pipeline — Products — Performance — Potential” report to their offering.

The Japanese pharmaceutical market has become increasingly difficult as National Health Insurance prices have been reduced and the larger pharma companies from Europe and the US have won a greater proportion of domestic market share. This competitive environment has seen three notable Japanese mergers in fiscal 2005 (to form Daiichi Sankyo, Astellas Pharma and Dainippon Sumitomo) and a general trend of struggling sales for Japanese companies. Takeda benefits from a more international profile than most Japanese companies, with nearly 50 per cent of sales generated overseas. This has allowed the company to steal a march on its domestic competitors and assert itself as the largest research-based pharmaceutical company in Japan and among the top twenty globally.

Takeda’s worldwide infrastructure lays the foundation for growth in the pharmaceutical market, but the main driver for expansion will always be the product portfolio. Actos, Lupron, Blopress and Takepron have provided the sales to enable 16 years of consistent revenue growth and pharmaceutical sales in excess of Â¥1 trillion. However, as outlined in Takeda’s 2006-2010 Medium-Term Plan, the key challenges facing the company are the patent expirations for Takepron (10th December 2005), Lupron (1st May 2006) and Actos (17th January 2011). Consequently, new markets, indications and formulations for these products dominate Takeda’s pipeline, and the company has indicated it will continue to invest heavily in the life-cycle management of these core drugs.

Pharmaceutical company intelligence reports provide a full review of the company’s activities together with five-year sales forecasts for its key products. The company’s financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company’s product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Contents:

EXECUTIVE SUMMARY

A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.

THERAPEUTIC AREA FOCUS

Key product analysis and forecasting

Metabolic

Actos (pioglitazone)

Basen (voglibose)

Cardiovascular

Blopress (candesartan cilexetil)

Gastrointestinal

Amitiza (lubiprostone)

Takepron/Prevacid/Zoton (lansoprazole)

Anticancer

Leuplin/Lupron/Enantone (leuprorelin acetate)

Musculoskeletal

Benet (risedronate)

Enbrel (etanercept)

Central Nervous System

Rozerem (ramelteon)

OPERATIONAL DATA

A wealth of background and detail

A full 5-year financial performance assessment

Key corporate events

Key agreements

Infrastructure

Subsidiaries and joint ventures

Companies Mentioned:

– 3M Pharmaceuticals

– Abbott

– Affymax Inc

– Alizyme plc

– Andrx Corporation

– ASKA Pharmaceutical, KI Pharma

– Cerexa Pharmaceuticals Inc

– Cephalon Inc

– Eli Lilly

– Evotec

– Galaxy Biotech

– Human Genome Sciences Inc (HGS)

– IL YANG Pharmaceutical Ltd

– Kissei Pharmaceutical Co Ltd

– Ligand Pharmaceuticals Inc

– Merck KGaA

– Mitsubishi Pharma Corporation

– Paradigm Therapeutics Ltd

– PPD Inc

– Pronova Biocare AS

– Santhera Pharmaceuticals AG

– Schering AG

– Sucampo Pharmaceuticals Inc

– Teijin Limited

– Toray Industries Ltd

For more information visit: http://www.researchandmarkets.com/reportinfo.asp?report_id=43085.

Source: Espicom Business Intelligence